|
| 6.1 - 7.8 | 6.1 - 11.1 | 7.8 - 10.0 | 3.9 - 11.1 | |
| n | 193 | 415 | 177 | 510 | |
| Age, median [Q1, Q3] | 51.00 [40.00, 65.00] | 55.00 [44.00, 65.00] | 57.00 [47.00, 66.00] | 54.00 [43.00, 65.00] | |
| Male, n | 114 | 249 | 105 | 307 | |
| Male, (%) | 59.07% | 60.00% | 59.32% | 60.20% | |
| ethnicity |
|
|
|
| |
| white, n | 126 | 256 | 109 | 312 | |
| white, (%) | 65.28% | 61.69% | 61.58% | 61.18% | |
| BLACK/AFRICAN AMERICAN, n | 21 | 51 | 25 | 59 | |
| BLACK/AFRICAN AMERICAN, (%) | 10.88% | 12.29% | 14.12% | 11.57% | |
| AMERICAN INDIAN/ALASKA NATIVE, n | 0 | 2 | 0 | 2 | |
| AMERICAN INDIAN/ALASKA NATIVE, (%) | 0.00% | 0.48% | 0.00% | 0.39% | |
| PORTUGUESE, n | 2 | 4 | 0 | 4 | |
| PORTUGUESE, (%) | 1.04% | 0.96% | 0.00% | 0.78% | |
| UNKNOWN, n | 24 | 50 | 20 | 63 | |
| UNKNOWN, (%) | 12.44% | 12.05% | 11.30% | 12.35% | |
| ASIAN, n | 5 | 12 | 4 | 14 | |
| ASIAN, (%) | 2.59% | 2.89% | 2.26% | 2.75% | |
| OTHER, n | 7 | 16 | 7 | 21 | |
| OTHER, (%) | 3.63% | 3.86% | 3.95% | 4.12% | |
| HISPANIC/LATINO, n | 5 | 13 | 5 | 21 | |
| HISPANIC/LATINO, (%) | 2.59% | 3.13% | 2.82% | 4.12% | |
| UNABLE TO OBTAIN, n | 3 | 11 | 7 | 14 | |
| UNABLE TO OBTAIN, (%) | 1.55% | 2.65% | 3.95% | 2.75% | |
| Aps III, median [Q1, Q3] | 56.00 [40.00, 79.00] | 62.00 [43.00, 87.50] | 64.00 [47.00, 89.00] | 59.00 [41.00, 84.00] | |
| inSOFA, median [Q1, Q3] | 1.00 [0, 3.00] | 1.00 [0, 4.00] | 1.00 [0, 4.00] | 1.00 [0, 4.00] | |
| ▲SOFA, median [Q1, Q3] | 1.00 [−1.00, 3.00] | 1.00 [−1.00, 3.00] | 1.00 [0, 3.00] | 1.00 [−1.00, 3.00] | |
| Glu_meana (mmol/L), median [Q1, Q3] | 6.90 [6.55, 7.38] | 7.88 [7.00, 8.92] | 8.56 [8.18, 9.18] | 7.55 [6.42, 8.61] | |
| Glu_cvb, median [Q1, Q3] | 0.21 [0.16, 0.25] | 0.23 [0.17, 0.33] | 0.26 [0.20, 0.37] | 0.22 [0.16, 0.31] | |
| Glu_frequency* (n/day), median [Q1, Q3] | 3.97 [2.58, 4.78] | 4.59 [3.63, 6.34] | 5.14 [4.19, 7.35] | 4.43 [3.24, 6.10] | |
| LOS in ICUc, median [Q1, Q3] | 4.99 [3.09, 12.61] | 5.83 [3.14, 13.74] | 5.96 [3.11, 14.05] | 4.95 [2.96, 11.67] | |
| LOS in hospitald, median [Q1, Q3] | 16.85 [10.62, 27.52] | 17.76 [9.99, 28.95] | 18.13 [8.83, 28.88] | 16.62 [9.03, 26.71] | |
| antibiotic day, median [Q1, Q3] | 1.00 [0, 3.00] | 1.00 [0, 3.00] | 1.00 [0, 3.00] | 1.00 [0, 3.00] | |
| die, n | 94 | 204 | 89 | 241 | |
| die, (%) | 48.70% | 49.16% | 50.28% | 47.25% | |
| blood-infection, n | 59 | 123 | 55 | 142 | |
| blood-infection, (%) | 30.57% | 29.64% | 31.07% | 27.84% | |
| Abdominal-infection, n | 24 | 60 | 24 | 71 | |
| Abdominal-infection, (%) | 12.44% | 14.46% | 13.56% | 13.92% | |
| urinary-infection, n | 20 | 45 | 22 | 57 | |
| urinary-infection, (%) | 10.36% | 10.84% | 12.43% | 11.18% | |
| respiratory-infection, n | 38 | 71 | 29 | 78 | |
| respiratory-infection, (%) | 19.69% | 17.11% | 16.38% | 15.29% | |
| diabetes, n | 25 | 135 | 82 | 148 | |
| diabetes, (%) | 12.95% | 32.53% | 46.33% | 29.02% | |
| hypoglycemia, n | 3 | 7 | 2 | 11 | |
| hypoglycemia, (%) | 2.63% | 2.81% | 1.90% | 3.58% | |
| die, n | 16 | 62 | 36 | 68 | |
| die, (%) | 8.29% | 14.94% | 20.34% | 13.33% | |
| hyperlipidemia, n | 29 | 85 | 47 | 96 | |
| hyperlipidemia, (%) | 25.44% | 34.14% | 44.76% | 31.27% | |